ICD Reimbursement Mortality by Intention-to-Treat Mortality Months of follow-up 36.1% 7.2% year.

Slides:



Advertisements
Similar presentations
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Advertisements

Sudden Cardiac Death Prevention: Clinical Trials Alena Goldman, MD September 9, 2004.
Device Therapy in Heart Failure
SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy Substrate Mapping and Ablation in Sinus Rhythm to Halt.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
La stratificazione del rischio aritmico oltre la frazione di eiezione Milano 17 Aprile 2009 Prof. Luigi Padeletti Heart Failure & Co.
Prevention de la Mort Subite Treatment of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death S. Nasr, M.D. Clinical Cardiac Electrophysiologist.
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Gillian D Sanders Ph.D.Lurdes Y Inoue Ph.D. Associate Professor of MedicineAssociate Professor of Biostatistics Duke UniversityUniversity of Washington.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
CRT-D Effectiveness by QRS Duration and Morphology in the MADIT-CRT Patients Wojciech Zareba, MD, PhD, Helmut Klein, MD, Iwona Cygankiewicz, MD, PhD, W.
ICDs for Heart Failure Derek T. Connelly President - Heart Rhythm UK Consultant Cardiologist - Glasgow Royal Infirmary September 2005.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
For the Long Haul: Improving Longevity After MI COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Journal Review-CRT Dr Pradeep Sreekumar Senior Resident Cardiology.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Management of Chronic Heart Failure SIGN 95
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial Bardy GH. N Engl J Med. 2005;352:
The Latest Device Therapy in W. Herts Dr Philip Moore.
AICD usage for primary prevention at Mercy Hospital: successes, challenges and next steps Mohammad Tahir PGY-3.
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.
Case Studies The results presented in these case studies are specific to these individual patients. Patient results will vary, not every response is the.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.
Heart Failure: ACC Guidelines for Dx and Management Steven W. Harris MHS PAC.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
An ICD for every CRT patient ?
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
4S: Scandinavian Simvastatin Survival Study
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
Complex Devices..... Biventricular Pacemaker: (aka Cardiac Resynchronisation Therapy) Treats subset of patients with heart failure Needs high quality.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
ICD’s: Current Roles and Evidence Shariff Attaya M.D. Senior Talk Case Western Reserve University.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Defibrillator in Acute Myocardial Infarction Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Drs. Stewart Connelly.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of the Wearable Cardioverter-Defibrillator.
Wearable Cardioverter Defibrillators
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
Defibrillator in Acute Myocardial Infarction Trial
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
The European Society of Cardiology Presented by Dr. Saman Rasoul
ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.
Recently Diagnosed vs Chronic HF Associated with Better Outcomes
CathPCI-NCDR Registry Mortality (STEMI)
Cardiovacular Research Technologies
DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)
Study Design Patients with LBBB and LV dysfunction
Outcome Relative risk with beta blockers 95% CI Stroke –1.30
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
The European Society of Cardiology Presented by RJ De Winter
Ischemic Postconditioning
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
MRRs and EMRRs for women with ACS
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Presentation transcript:

ICD Reimbursement

Mortality by Intention-to-Treat Mortality Months of follow-up 36.1% 7.2% year

Mortality by Intention-to-Treat Mortality Months of follow-up

Mortality by Intention-to-Treat Mortality Months of follow-up

DEFINITE Mortality – NYHA FC III No. at Risk Standard ICD Survival Time in Years ICD Standard Probability of Survival 1.0 p=0.009; RR=0.33 STD=16/49 (33%) ICD= 6/47 (13%)

ICD Workup LVEF ≤ 35% NYHA FC QRS Duration (120 ms) Ischemic or nonischemic Cardiomyopathy Duration of NIDCM (3 vs 9 months) Time since last Myocardial Infarction 40 days Time since last PCI or CABG 3 months

ICD Workup Echo 40 days from MI 3 months from PCI or CABG Dyssynchrony if QRS < 120 ms NYHA FC On Beta Blockers & ACE Inibitor QRS Duration (120 ms) No ongoing need for revascularization

Scheduling ICD Implant After CABG or PCI 3 month return, D/C on Beta Blocker & ACE 2D echo, ECG EP consult ICD or BiV ICD prescheduled Determined by NYHA and FC After MI 40 day return, D/C on Beta Blocker & ACE 2D echo, ECG EP consult ICD or BiV ICD prescheduled Determined by NYHA and FC

Scheduling ICD Implant After NIDCM Diagnosis – plan IRB Trial 3 month return, D/C on Beta Blocker & ACE 2D echo, ECG EP consult ICD or BiV ICD prescheduled Determined by NYHA and FC After NIDCM Diagnosis – No planned IRB Trial 9 month return, D/C on Beta Blocker & ACE 2D echo, ECG EP consult ICD or BiV ICD prescheduled Determined by NYHA and FC